Gösterilen 1 - 14 sonuçlar arası kayıtlar. 14 sonuç. Aranan kelime 'Dally, L', Sorgu süresi: 0.04s Sonuçları Daraltın
  1. 1
    Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: lessons from a Malaria vaccine trial substudy

    Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: lessons from a Malaria vaccine trial substudy Yazar: Ford, T, Wenden, C, Mbekeani, A, Dally, L, Cox, J, Morin, M, Winstone, N, Hill, A, Gilmour, J, Ewer, K

    Baskı/Yayın Bilgisi 2017
    Journal article
  2. 2
    OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial

    OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial Yazar: Francis D, Tartaglia J, Rerks-Ngam S, Dally L, Nitayaphan S, Ratto-Kim S, Jongrakthaitae S, Phuang-ngem Y, Chuenarom W, Schuetz A, Trichavaroj R, de Souza MS, Michael NL, Paris RM, Kim JH

    Baskı/Yayın Bilgisi 2009-10-01
    Makale
  3. 3
    A phase 1 human immunodeficiency virus vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens

    A phase 1 human immunodeficiency virus vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost v... Yazar: Kratochvil, S, McKay, P, Kopycinski, J, Bishop, C, Hayes, P, Muir, L, Pinder, C, Cizmeci, D, King, D, Aldon, Y, Wines, B, Hogarth, P, Chung, A, Kent, S, Held, K, Geldmacher, C, Dally, L, Santos, N, Cole, T, Gilmour, J, Fidler, S, Shattock, R

    Baskı/Yayın Bilgisi 2017
    Journal article
  4. 4
    Corrigendum to "Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers" [Vaccine 26 (2008) 6671-6677] (DOI:10.1016/j.vaccine.2008.09.016)

    Corrigendum to "Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to in... Yazar: Guimarães-Walker, A, Mackie, N, McCormack, S, Hanke, T, Schmidt, C, Gilmour, J, Barin, B, McMichael, A, Weber, J, Legg, K, Babiker, A, Hayes, P, Gotch, F, Smith, C, Dally, L, Dorrell, L, Cebere, I, Kay, R, Winstone, N, Moore, S, Goonetilleke, N, Fast, P

    Baskı/Yayın Bilgisi 2011
    Journal article
  5. 5
    Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

    Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 speci... Yazar: Guimarães-Walker, A, Mackie, N, McCormack, S, Hanke, T, Schmidt, C, Gilmour, J, Barin, B, McMichael, A, Weber, J, Legg, K, Babiker, A, Hayes, P, Gotch, F, Smith, C, Dally, L, Dorrell, L, Cebere, I, Kay, R, Winstone, N, Moore, S, Goonetilleke, N, Fast, P

    Baskı/Yayın Bilgisi 2008
    Journal article
  6. 6
    Corrigendum to " Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers" [Vaccine 26 (2008) 6671-6677]

    Corrigendum to " Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to i... Yazar: Guimarães-Walker, A, Mackie, N, McCormack, S, Hanke, T, Schmidt, C, Gilmour, J, Barin, B, McMichael, A, Weber, J, Legg, K, Babiker, A, Hayes, P, Gotch, F, Smith, C, Dally, L, Dorrell, L, Cebere, I, Kay, R, Winstone, N, Moore, S, Goonetilleke, N, Fast, P

    Baskı/Yayın Bilgisi 2011
    Journal article
  7. 7
    Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers (vol 26, pg 6671, 2008)

    Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 speci... Yazar: Guimaraes-Walker, A, Mackie, N, McCormack, S, Hanke, T, Schmidt, C, Gilmour, J, Barin, B, McMichael, A, Weber, J, Legg, K, Babiker, A, Hayes, P, Gotch, F, Smith, C, Dally, L, Dorrell, L, Cebere, I, Kay, R, Winstone, N, Moore, S, Goonetilleke, N, Fast, P, Grp, I

    Baskı/Yayın Bilgisi 2011
    Journal article
  8. 8
    Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.

    Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. Yazar: Stevens, W, Kamali, A, Karita, E, Anzala, O, Sanders, E, Jaoko, W, Kaleebu, P, Mulenga, J, Dally, L, Fast, P, Gilmour, J, Farah, B, Birungi, J, Hughes, P, Manigart, O, Stevens, G, Yates, S, Thomson, H, von Lieven, A, Krebs, M, Price, M, Stoll-Johnson, L, Ketter, N

    Baskı/Yayın Bilgisi 2008
    Journal article
  9. 9
    OA05-01. <it>In vivo </it>electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers

    OA05-01. <it>In vivo </it>electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers Yazar: Park H, Schmidt C, Smith C, Dally L, Clark L, Cheeseman H, Gill DK, Tarragona T, Cox J, Huang Y, Andersen J, Caskey M, Vittorino RM, Boente-Carrera MM, Dugin DP, Gardiner DF, Hannaman D, Schlesinger SJ, Hurley A, Vasan S, Sayeed E, Gilmour J, Fast P, Bernard R, Ho DD

    Baskı/Yayın Bilgisi 2009-10-01
    Makale
  10. 10
    Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.

    Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Yazar: Jaoko, W, Nakwagala, F, Anzala, O, Manyonyi, G, Birungi, J, Nanvubya, A, Bashir, F, Bhatt, K, Ogutu, H, Wakasiaka, S, Matu, L, Waruingi, W, Odada, J, Oyaro, M, Indangasi, J, Ndinya-Achola, J, Konde, C, Mugisha, E, Fast, P, Schmidt, C, Gilmour, J, Tarragona, T, Smith, C, Barin, B, Dally, L

    Baskı/Yayın Bilgisi 2008
    Conference item
  11. 11
    Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.

    Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenici... Yazar: Peters, B, Jaoko, W, Vardas, E, Panayotakopoulos, G, Fast, P, Schmidt, C, Gilmour, J, Bogoshi, M, Omosa-Manyonyi, G, Dally, L, Klavinskis, L, Farah, B, Tarragona, T, Bart, P, Robinson, A, Pieterse, C, Stevens, W, Thomas, R, Barin, B, Mcmichael, A, McIntyre, J, Pantaleo, G, Hanke, T, Bwayo, J

    Baskı/Yayın Bilgisi 2007
    Conference item
  12. 12
    Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

    Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and mo... Yazar: Goonetilleke, N, Moore, S, Dally, L, Winstone, N, Cebere, I, Mahmoud, A, Pinheiro, S, Gillespie, G, Brown, D, Loach, V, Roberts, J, Guimaraes-Walker, A, Hayes, P, Loughran, K, Smith, C, De Bont, J, Verlinde, C, Vooijs, D, Schmidt, C, Boaz, M, Gilmour, J, Fast, P, Dorrell, L, Hanke, T, Mcmichael, A

    Baskı/Yayın Bilgisi 2006
    Journal article
  13. 13
    Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults

    Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults Yazar: Mutua, G, Farah, B, Langat, R, Indangasi, J, Ogola, S, Onsembe, B, Kopycinski, J, Hayes, P, Borthwick, N, Ashraf, A, Dally, L, Barin, B, Tillander, A, Gilmour, J, De Bont, J, Crook, A, Hannaman, D, Cox, J, Anzala, O, Fast, P, Reilly, M, Chinyenze, K, Jaoko, W, Hanke, T, HIV-CORE 004 study group

    Baskı/Yayın Bilgisi 2017
    Journal article
  14. 14
    CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.

    CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. Yazar: Karita, E, Ketter, N, Price, M, Kayitenkore, K, Kaleebu, P, Nanvubya, A, Anzala, O, Jaoko, W, Mutua, G, Ruzagira, E, Mulenga, J, Sanders, E, Mwangome, M, Allen, S, Bwanika, A, Bahemuka, U, Awuondo, K, Omosa, G, Farah, B, Amornkul, P, Birungi, J, Yates, S, Stoll-Johnson, L, Gilmour, J, Stevens, G, Shutes, E, Manigart, O, Hughes, P, Dally, L, Scott, J, Stevens, W, Fast, P, Kamali, A

    Baskı/Yayın Bilgisi 2009
    Journal article

Arama Araçları: